Watch the video and download the slides


GU cancer update by Dr. Elena Castro, Hospital Universitario Virgen de la Victoria, Málaga, Spain.

Hi my name is Elena Castro, I’m a medical oncologist at Hospital Universitario Virgen de la Victoria in Malaga in Spain and I’m going to comment on some abstracts presented at ESMO 2021 that I believe are very relevant for our clinical practice.

Which abstracts did you select and why?

I have selected two abstracts presented in the presidential symposium.

The first one by Dr. Attard who presented on patients with high-risk localised disease included in the STAMPEDE trial treated with abiraterone with or without enzalutamide.

The second abstract was presented by Dr. Fizazi, he presented data on the addition of abiraterone for the treatment of patients with metastatic hormone-sensitive prostate cancer, who may also have received docetaxel.

He has already presented data on radiographic progression free survival earlier at ASCO this year but here he has presented overall survival data.

What are the main conclusions?

The main conclusion of the STAMPEDE data presented here is that patients with high risk localised prostate cancer benefit from the addition of two years of treatment with abiraterone.

The conclusion of the PEACE-1 study presented at ESMO 2021 is that patients with metastatic hormone-sensitive prostate cancer, particularly those with high volume disease benefit from intensified therapy with docetaxel and abiraterone.

What are the implications of this data for clinical practice?

What we’ve learned from the data presented from STAMPEDE and PEACE-1 is that for patients with a higher risk of progression, either in the localised setting or in the metastatic hormone-sensitive setting, intensifying therapies can improve their survival.

Were there any other presentations of interest?

Dr. Armstrong has presented the final survival data of the ARCHES trial that demonstrates the benefits of treating patients with metastatic hormone-sensitive prostate cancer with enzalutamide and is in line with the results of other trials addressing the benefit of other androgen receptor inhibitors in this setting.

And also a study from the Swiss group in which the investigators assess the role of continuous daralutamide after treatment with docetaxel in patients with metastatic castration-resistant prostate cancer.

What are your take-home messages from ESMO 2021?

I believe that from now on we will be using the androgen receptor signaling inhibitors more and more in earlier stages and we have more and more evidence that suggests that sequencing these therapies is probably not the best approach for our patients but as we have seen at ESMO, there are many other drugs that are being investigated for mCRPC and we are likely to be using these new therapies with new mechanisms of actions in the advanced stages.

On behalf of GU CONNECT, thank you for listening and don’t forget to visit the COR2ED website if you would like to download the slides.

Dr Elena Castro is a Consultant Medical Oncologist at Hospital Universitario 12 de Octubre in Madrid, Spain.  She treats patients with advanced bladder and prostate cancer, most of them within the context of clinical trials. She studied medicine and obtained a PhD from the University of Salamanca, Spain.  After training in medical oncology, she completed a four-year fellowship in Cancer Genetics at the Institute of Cancer Research, UK.   Later, she joined the Spanish National Cancer Research Center as a clinician-scientist.  Her research has focused on addressing the clinical implications of genetic and genomic variants in prostate cancer, receiving several awards for her work. She has also authored numerous articles published in international peer-reviewed journals including some relevant papers on the impact of germline variants in prostate cancer.   

Dr Elena Castro has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AstraZeneca, Bayer, Janssen, MSD, Novartis, Pfizer, Synlab and Telix. 

A CONNECT Update from ASCO GU 2018

Episode

1

of

episodes
GU CONNECT
Experts
Assoc. Prof. Tanya Dorff
  • download Downloadable
    Resouces
  • clock 5 MIN
  • calendar Oct 2021
This educational programme is supported by an Independent Medical Education Grant from Bayer
GU CONNECT update from Orlando

Episode

1

of

episodes
GU CONNECT
Experts
Assoc. Prof. Alicia Morgans
  • download Downloadable
    Resouces
  • clock 5 MIN
  • calendar Oct 2021
This educational programme is supported by an Independent Medical Education Grant from Bayer
Experts
Prof. Neeraj Agarwal
  • download Downloadable
    Resouces
  • clock 5 MIN
  • calendar Oct 2021
This educational programme is supported by an Independent Medical Education Grant from Bayer
Experts
Dr Fabio Schutz
  • download Downloadable
    Resouces
  • clock 5 MIN
  • calendar Oct 2021
This educational programme is supported by an Independent Medical Education Grant from Bayer
Experts
Prof. Gerhardt Attard
  • download Downloadable
    Resouces
  • clock 5 MIN
  • calendar Oct 2021
This educational programme is supported by an Independent Medical Education Grant from Bayer
Programme summary
Watch the video now
Share this programme
This educational programme is supported by an Independent Medical Education Grant from Bayer
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GU CONNECT

GU CONNECT is an initiative of COR2ED, supported by Independent Educational Medical Grants from Bayer, AstraZeneca and Eisai Europe Limited.

Meet the experts

Other programmes of interest

podcast Podcast
Oncology 
Perseverance in molecular testing in NSCLC pays off

Looking beyond the obvious mutations in non-small-cell lung cancer

Experts
Prof. Frédérique Penault-Llorca, Prof. Mark Socinski
  • download Downloadable
    Resources
  • clock 26 MIN
  • calendar Mar 2024

Educational programme supported by an Independent Medical Education grant from Bayer
conference-update Conference update
Oncology 
ER+ advanced breast cancer: Highlights from EBCC-14 satellite symposium

Medical experts discuss current and upcoming treatment strategies to use after CDK4/6 inhibitors in patients with ER+/HER2- advanced breast cancer

Experts
Prof. Valentina Guarneri, Prof. Matteo Lambertini, Prof. Federico Rojo
  • download Downloadable
    Resources
  • clock 6 MIN
  • calendar Mar 2024

Educational programme supported by an Independent Medical Education grant from Menarini Stemline.
interactive-patient-case Interactive patient case
Oncology 
TRK fusion-positive lung cancer: Diagnosis and treatment

Make decisions for your patient at two key stages in their journey

Experts
Prof. Fernando López-Ríos, Prof. Mark Socinski
  • clock 60 MIN
  • calendar Mar 2024

Educational programme supported by an Independent Medical Education grant from Bayer
conference-update Conference update
Oncology 
ESMO 2023: Lung cancer update

Experts discuss new lung cancer data at a meeting hosted by eChinaHealth and COR2ED

  • clock 43 MIN
  • calendar Mar 2024

Educational programme supported by an Independent Medical Education grant from This educational programme is supported by an Independent Medical Education Grant from SystImmune and BeiGene Europe.
other Other
Oncology 
Lung cancer survey: Patient views on biomarker testing

Share the survey with patients with lung cancer and their caregivers

Experts
Prof. Christian Rolfo, Prof. Fernando López-Ríos
Endorsed by
LUNGevity
Lung Cancer Europe IASLC
The Israeli Lung Cancer Foundation ISLB
  • download Downloadable
    Resources
  • clock 2 MIN
  • calendar Mar 2024

Educational programme supported by an Independent Medical Education grant from Bayer.
podcast Podcast
Oncology 
Precision oncology approaches in lung cancer

Explore pre-analytical phase challenges and biomarker testing in lung cancer. Moderated by the Oncology Brothers.

Experts
Dr Bruna Pellini, Dr Semir Vranić, Oncology Brothers (Moderators)
Endorsed by
AMP
  • download Downloadable
    Resources
  • clock 25 MIN
  • calendar Mar 2024

Educational programme supported by an Independent Medical Education grant from AstraZeneca and Amoy Diagnostics.